JG Chemicals Ltd. Share Price

TORRENT PHARMA — CHRONIC CARE, GLOBAL SCALE 💊🚀

In pharma, the strongest businesses don't just sell medicines. They build brands that doctors keep prescribing year after year. Torrent Pharma is building exactly that. FY26 showed the strength of the platform. Revenue reached ₹13,980 crore, up 21%, while operating EBITDA climbed 23% to ₹4,559 crore. Even excluding JB Pharma, the base business grew revenue 15% with a healthy 32.7% EBITDA margin. Now the bigger story is chronic therapies. Cardiology. CNS. Gastro. Diabetology. Women's healthcare. These aren't one-time purchases. They are recurring therapies where strong brands, doctor relationships and distribution can create durable revenue streams. Torrent already ranks among India's leaders across several of these segments. And then came JB Chemicals. The integration has expanded Torrent's domestic franchise and, according to the company's FY26 annual report, lifted the combined business to 5th position in the Indian pharmaceutical market, from 7th earlier. The international engine adds another layer. Torrent operates across 50+ countries, with particularly strong positions in markets including Brazil and Germany. And this isn't a business cutting back on innovation. FY26 R&D spending reached ₹650 crore, up 12%, showing continued investment behind future products and differentiated therapies. The formula is becoming powerful: Chronic therapies → Recurring demand Strong brands → Pricing power JB Pharma → Larger domestic platform Global markets → Geographic diversification R&D → Future product pipeline Of course, pharma isn't risk-free. Regulatory action, pricing pressure, product concentration, integration execution and US-market volatility can impact earnings. But Torrent's advantage is increasingly clear: A strong domestic franchise + chronic-care leadership + global presence + acquisition-led scale. The company isn't chasing every pharma opportunity. It's building depth where prescription demand can compound.

See More

JG Chemicals Ltd ₹1.10 dividend the 25th AGM on September 30

JG Chemicals has fixed September 23, 2026 as the record date for its FY26 final dividend of ₹1.10 per equity share (11% on ₹10 face value), subject to approval at the 25th AGM on September 30, 2026 (3:30 pm IST via VC/OAVM). The company also scheduled a virtual group analyst/institutional investor meet on September 16, 2026 at 10 am, and held in‑person investor meets in Mumbai on September 7–8, 2026. On the operational front, its subsidiary acquired about 16.74 acres in Andhra Pradesh for ₹18.41 crore in August to support future capacity expansion. Shares closed around ₹567.30 on September 15 (down ~4.2% on the day), with a 52‑week high near ₹656.40 and a recent bulk deal of 315,935 shares at ₹656.40 on August 28.

See More

Torrent Pharma currently has a strong fundamental setup

1. JB Chemicals merger — major structural trigger The JB Chemicals amalgamation became effective in July 2026. The combination substantially increases Torrent's India franchise and creates cost synergies. Management has raised its first-year JB cost-synergy expectation to more than ₹100 crore, above the earlier ₹90 crore target. 2. Strong India business India revenue grew 19%, significantly ahead of the Indian pharma market's ~12% growth. Torrent also became the market leader in cardiac therapies. 3. Semaglutide opportunity Torrent has launched Sembolic and Semalix, covering injectable and oral semaglutide for diabetes and obesity. Its semaglutide portfolio already achieved about 36% market share during Q1 FY27. This could become a meaningful long-term growth driver as India's obesity/diabetes treatment market expands. 4. International recovery US revenue increased 36% to ₹418 crore, helped by new launches and certain one-time opportunities, while Brazil grew 27%. Germany was weaker at +3% because of supplier disruptions and lower tender offtake. 5. Manufacturing/regulatory position Torrent's Bileshwarpura oncology facility received a zero-observation USFDA inspection in April 2026, which is a positive regulatory signal.

See More

SWOT Analysis – Torrent Pharmaceuticals Limited

Strengths Strong market position in branded generic medicines, particularly in cardiology, gastroenterology, diabetology, and central nervous system (CNS) therapies. Wide international presence, with operations across India, Brazil, Germany, the United States, and several other countries. Strong research and development (R&D) capabilities supporting new product development and regulatory approvals. Healthy financial performance with consistent revenue growth, profitability, and strong cash generation. Weaknesses Dependence on branded generics, making the company vulnerable to pricing pressure and increased competition. Exposure to regulatory risks, particularly in export markets where compliance standards are stringent. Product recalls or quality issues can affect brand reputation and financial performance. Opportunities Growing global demand for generic medicines, especially in emerging markets. Strategic acquisitions and expansion, such as the acquisition of JB Chemicals, to strengthen market share and product portfolio. Expansion into innovative medicines and specialty therapies, alongside its traditional generics business. Increasing healthcare spending and aging populations worldwide create long-term demand for pharmaceuticals. Threats Intense competition from Indian and multinational pharmaceutical companies. Strict government regulations and pricing controls in domestic and international markets. Patent litigation and regulatory inspections that may delay product launches. Fluctuating raw material (API) costs and supply-chain disruptions affecting manufacturing costs.

See More

Torrent Pharma Gets Listing Approval for JB Chemicals Merger Shares

💊

has received final approval to list 4.19 crore equity shares issued under the amalgamation scheme with JB Chemicals & Pharmaceuticals Limited. The newly issued shares will commence trading on the NSE and BSE from July 28, 2026.

See More

### Stocks in News ##

: Partnered with Databricks to help enterprises modernize data infrastructure and deploy AI at scale. Impact: Positive; strengthens AI and cloud services portfolio. ## : Partner Philogen resubmitted the European marketing application for Nidlegy. Impact: Positive; supports potential regulatory approval in key international markets. ## (DMart): Opened a new store in Udaipur, taking the total store count to 505. Impact: Positive; supports retail expansion. ## : Approved raising up to ₹4,500 crore via NCDs/bonds to refinance debt. Impact: Neutral to Positive; improves financial flexibility. ## : Signed an ECI agreement for a utility-scale solar + BESS project in New Zealand. Impact: Positive; marks international expansion. ## : Income Tax Department reduced the FY22 tax demand from ₹327.44 crore to ₹9.46 crore. Impact: Positive; significantly lowers tax liability. ## : Flooding temporarily disrupted operations at its Sanand plant. Impact: Mildly Negative; short-term production impact. ## : Launched its QIP with a floor price of ₹1,698.15 per share. Impact: Neutral; fundraising supports growth but may lead to near-term dilution. ## : NSE and BSE approved listing of shares issued under the JB Chemicals amalgamation. Impact: Neutral; procedural post-merger development. ## : Reported a cybersecurity incident involving potential business email compromise, with no material operational impact. Impact: Neutral; the bank stated there is no material impact on operations or financial performance. ## : Increased its stake in TVS Credit Services to 85.15% by acquiring an additional 4.39% stake. Impact: Positive; strengthens control over the financing business. !

See More